|
Interferon beta-1a
resources
|
|
|
|
|
|
DRUG INFO
Interferon beta-1a
Drug Name:
Interferon beta-1a
Indication: For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
Pharmacology: Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.
Mechanism Of Action: Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
Drug Category: Antiviral Agents; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Interferon beta precursor;IFN-beta;Fibroblast interferon; Avonex (Biogen Inc)
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human interferon beta
Chemical Formula: C908H1408N246O252S7
Half Life: 10 hrs
Drug Type: Approved Drug
# Accession No: BIOD00093
CAS Registry Number: 145258-61-3
|
|
|
|
|
|
Interferon beta-1a News
(When available)
Biogen Idec Could See Growth Slow For Avonex Dec 16, 2005
Forbes BIIB - news - people ) with a "neutral" rating and $47 price target, expecting growth to slow for the company's multiple sclerosis drug, Avonex, as investors ...
Rivals Glaxo, Novartis reported close to making bids for Serono Jan 12, 2006
Boston Globe, Biogen Idec Inc.'s Avonex leads the market for medicines to treat multiple sclerosis -- a central nervous system disease that affects about 2 million people ...
Novartis, Glaxo Close to Bids for Serono, People Say (Update1) Jan 11, 2006
Bloomberg Biogen Idec Inc.'s Avonex leads the market, bringing in $1.42 billion in sales in 2004. Schering AG's Betaseron had sales of 782 million euros ($944 million). ...
Novartis, Glaxo Close to Bids for Serono, People Say (Update2) Jan 11, 2006
Bloomberg Serono. Biogen Idec Inc.'s Avonex leads the market for multiple sclerosis medicines, bringing in $1.42 billion in sales in 2004. ...
Serono changes tack Jan 9, 2006
Nature.com (subscription), However, despite longstanding claims of Rebif's superior efficacy, it has so far failed to dislodge Avonex (interferon -1a), marketed by Biogen Idec, of ...
Biogen: FDA to rule on Tysabri Jan 10, 2006
MarketWatch ...effects. The one great exception, he said, is a group of drugs known as interferons, which includes Biogen's widely prescribed Avonex. ...
Can Mass. prevent the next Biogen Idec from leaving? Dec 19, 2005
MSNBC Over $260 million in expansion has taken place since the company started using the site to manufacture Avonex, a multiple sclerosis treatment that went on to ...
As biotech drug prices rise, US hunts for solution Dec 28, 2005
Pittsburgh Post Gazette, For example, Biogen Idec Inc., after a fallout with a business partner that manufactured the multiple sclerosis drug Avonex for clinical trials, changed to a ...
|
|
|
